Insmed Incorporated

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Insmed Incorporated 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About INSM

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. 

CEO
William H. Lewis
CEOWilliam H. Lewis
Employees
1,664
Employees1,664
Headquarters
Bridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded
1988
Founded1988
Employees
1,664
Employees1,664

INSM Key Statistics

Market cap
32.34B
Market cap32.34B
Price-Earnings ratio
-23.21
Price-Earnings ratio-23.21
Dividend yield
Dividend yield
Average volume
2.65M
Average volume2.65M
High today
$150.57
High today$150.57
Low today
$146.43
Low today$146.43
Open price
$147.00
Open price$147.00
Volume
1.75M
Volume1.75M
52 Week high
$212.75
52 Week high$212.75
52 Week low
$60.40
52 Week low$60.40

Stock Snapshot

As of today, Insmed Incorporated(INSM) shares are valued at $150.02. The company's market cap stands at 32.34B, with a P/E ratio of -23.21.

On 2026-02-26, Insmed Incorporated(INSM) stock moved within a range of $146.43 to $150.57. With shares now at $150.02, the stock is trading +2.5% above its intraday low and -0.4% below the session's peak.

Trading activity shows a volume of 1.75M, compared to an average daily volume of 2.65M.

The stock's 52-week range extends from a low of $60.40 to a high of $212.75.

The stock's 52-week range extends from a low of $60.40 to a high of $212.75.

INSM News

TipRanks 2d
Insmed price target lowered to $204 from $211 at Mizuho

Mizuho lowered the firm’s price target on Insmed (INSM) to $204 from $211 and keeps an Outperform rating on the shares post the Q4 report. The company offered “...

Simply Wall St 3d
Assessing Insmed Valuation After Brinsupri Outperformance And Upgraded 2026 Revenue Guidance

Insmed (INSM) has been in focus after its fourth quarter and full year 2025 earnings, where strong revenue from ARIKAYCE and new drug BRINSUPRI contrasted with...

Assessing Insmed Valuation After Brinsupri Outperformance And Upgraded 2026 Revenue Guidance
TipRanks 6d
Insmed price target raised to $211 from $209 at BofA

BofA analyst Jason Zemansky raised the firm’s price target on Insmed (INSM) to $211 from $209 and keeps a Buy rating on the shares. Though “absent much suspense...

Analyst ratings

95%

of 21 ratings
Buy
95.2%
Hold
4.8%
Sell
0%

More INSM News

TipRanks 6d
Insmed: Early Brinsupri Momentum but Policy Uncertainty and 2026 Pipeline Catalysts Justify Hold Rating

Analyst Maxwell Skor from Morgan Stanley maintained a Hold rating on Insmed and increased the price target to $166.00 from $162.00. Maxwell Skor has given his...

People also own

Based on the portfolios of people who own INSM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.